William Ho, IN8bio president, CEO and co-founder
In glimpse of tiny patient group, IN8bio’s ‘off-the-shelf’ gamma delta T cells remain durable
Seven months after dropping some very limited, but promising, data on three patients who received its gamma delta T cell treatment for leukemia, IN8bio revealed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.